This next generation of FRET-based biosensor cells is a novel tool to study tau seeding activity in Alzheimer’s disease human samples, especially in samples with low levels of seeding activity, which may help studying early tau-related pathological events. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.